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Abstract 
Purpose: Annual influenza immunization in medical risk groups is recommended in many countries. 
Recent evidence suggests that repeated inactivated influenza vaccine (IIV) immunization throughout 
childhood may impair long-term immunity against influenza. We assessed whether prior immunization 
altered the effect of IIV in children with pre-existing medical conditions on primary care diagnosed 
respiratory illness (RI) episodes during the influenza season. 
Methods: Electronic records of IIV immunized children who met the criteria for annual IIV 
immunization according to Dutch guidelines were extracted from a primary care database over 2004-
2015. For each year, we collected information on IIV immunization status, primary care attended RI 
episodes (including influenza-like illness, acute RI and asthma exacerbation) and potential confounders. 
Generalized estimating equations were used to model the association between prior IIV and occurrence of 
at least one RI episode during the influenza season with “current year immunized, but without IIV 
history” as reference group. 
Results: 4,183 children (follow-up duration: 11,493 child-years) were IIV immunized at least once. 
Adjusted estimates showed lower odds for RI in current year immunized children with prior IIV 
compared to those without (OR: 0.61;95%CI:0.47-0.78 for “current year immunized and one IIV in 
previous two years”; OR:0.85;95%CI:0.68-1.07 for “current year immunized and ≥2 IIVs in previous 
three years, including prior year”).  
Conclusion: Repeated IIV immunization in children with pre-existing medical conditions has no negative 
impact on, and may even enhance, long-term protection against RI episodes diagnosed during the 
influenza season in primary care. 
Keywords: Influenza, immunization, pre-existing medical condition, children, pediatrics, respiratory 
illness. 
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Abbreviations: ARTI: acute respiratory tract infection; ATC: anatomical therapeutic chemical; CI: 
confidence interval; GEE: generalized estimated equations; GP: general practitioner; ICPC: international 
classification for primary care; IIV: inactivated influenza vaccine; ILI: influenza like illness; JHN: Julius 
General Practitioner Network; OR: odds ratio; RI: respiratory illness; SCP: The Netherlands Institute for 
Social Research; SES: socio-economic status; URTI: upper respiratory tract infection; ZGA: The 
Healthcare Network Almere 
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Introduction 
Influenza is a leading cause of respiratory illness (RI) and healthcare resource use worldwide.[1] 
Influenza infection and associated complications pose a particular threat to individuals with pre-existing 
medical conditions such as chronic respiratory or cardiovascular disease and diabetes mellitus.[2] In 
contrast with policies in some other countries like the US, where all children are recommended to receive 
annual influenza immunization, seasonal immunization with inactivated influenza vaccine (IIV) for 
individuals with pre-existing medical conditions aged six months and above is therefore recommended in 
many European countries, including the Netherlands.[3] However, concerns exist about possible 
attenuation of influenza immunity following repeated IIV immunization. This may be particularly 
relevant to children with pre-existing medical conditions as they tend to receive IIV repeatedly throughout 
childhood and possibly into adult life. 
Possible immunological mechanisms for altering IIV effectiveness after repeated IIV immunization 
include interference with antibody and effector B-cell responses, depending on both the antigenic distance 
among vaccine strains and between the vaccine strains and circulating influenza strains [4, 5], and 
hampered development of cross-reactive virus-specific CD8+ T cells.[6] Children without any prior 
immunity from natural influenza could particularly be affected by the suppressed development of 
heterosubtypic immunity against antigenically distinct influenza strains.[7, 8]   
Epidemiological studies have shown conflicting results as to whether these immunological mechanisms 
impact protection from annually repeated immunization against influenza and RI during the influenza 
season. Most studies included only a limited number of consecutive influenza seasons which may lead to 
biased results since IIV effectiveness can vary substantially from year-to-year.[9-15] Furthermore, 
previous studies focused either on healthy children or on adults.[11, 16-21] Data on the impact of 
repeated influenza immunization in children with pre-existing medical conditions are therefore lacking 
completely. 
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Using routine longitudinal primary care data over the years 2004-2015, we therefore assessed whether the 
impact of IIV on general practitioner (GP) diagnosed RI episodes during influenza season was altered in 
immunized children with pre-existing medical conditions with a history of IIV immunization. As 
confirmation of influenza infection is rarely obtained in primary care, we used a composite outcome of RI 
strongly associated with influenza. 
 
Methods 
Study design and data collection 
For this observational cohort study, we extracted data from two large electronic primary care databases; 
the Julius General Practitioner Network (JHN) and The Healthcare Network Almere (ZGA) databases. 
These contain anonymous routine healthcare data of all patients enlisted in the participating primary care 
practices in the Utrecht and Almere region, centrally located in the Netherlands. The patient populations 
are representative of the general Dutch population.[22, 23]  
For Dutch residents, registration with a primary care practice is mandatory; GPs act as gatekeepers to 
specialized and hospital care, both during and outside office hours. Patient information in the databases 
includes diagnoses coded according to the International Classification for Primary Care (ICPC), drug 
prescriptions classified according to the Anatomical Therapeutic Chemical (ATC) Classification System 
and immunization codes.[24] GPs were trained to use this system and apply strict criteria for each ICPC 
code.  
Study population 
In the Netherlands, only children with pre-existing medical conditions are eligible for annual IIV 
immunization. Data for the years 2004-2015 of all children aged 6 months to 18 years eligible for annual 
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IIV immunization according to Dutch guidelines were extracted from the healthcare databases.[25, 26] 
Annual IIV immunization eligibility for this study was based upon pre-specified ICPC codes in the period 
between December 1st of the previous year and November 30th of the current year and pre-specified ATC 
codes in the period between July 1st and November 30th of the current year. This method was adopted 
from the national annual report on IIV coverage in the Dutch population.[25] The pre-existing medical 
conditions qualifying for IIV eligibility included respiratory (e.g. recurrent wheeze/asthma), pre-existing 
cardiovascular disease (e.g. congenital cardiovascular anomalies ), diabetes mellitus, renal failure or 
immunocompromising conditions.[27]  
All children receiving IIV at least once were included in the analysis. Each child was followed over time 
from the first IIV until either the i) year of last IIV immunization, ii) end of registration at the 
participating primary care practice or iii) or end of extraction date. 
Definition of outcomes 
As confirmation of influenza infection is rarely obtained in primary care, we used a composite outcome of 
RI strongly associated with influenza. The outcome was defined as occurrence of at least one GP-
diagnosed RI episode during the influenza season (yes/no) and included the following conditions and 
ICPC codes: i) influenza-like illness (ILI); R80 (influenza), ii) acute respiratory infection (ARI); H71 
(acute otitis media), R05 (cough), R78 (acute bronchitis/bronchiolitis), R81 (pneumonia), or iii) asthma 
exacerbation; R02 (dyspnea), R91 (chronic bronchitis), R96 (asthma). To exclude chronic RI not 
associated with an acute infection, ICPC codes R02, R05, R91 and R96 were only included if combined 
with a new prescription of inhaled or oral corticosteroids (ATC codes R03, H02AB) and/or oral 
antibiotics (ATC codes J01). To exclude ARI infections that are less specific for influenza, ICPC code 
R74 (URTI) was not included in the outcome. A new RI episode was documented after a consultation-
free interval of at least 28 days. A medical prescription was considered related when dated seven days 
before until seven days after the RI episode.  
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Influenza seasons 2004-2015 
Yearly influenza epidemic periods between 2004 and 2015 were defined as those weeks with at least 5% 
positive influenza isolates according to the sentinel surveillance of the National Institute for Public Health 
and the Environment (RIVM).[28] GPs participating in the sentinel surveillance randomly select patients 
presenting with ILI and/or ARI for collection of nasopharyngeal swabs. Samples are analyzed at the 
RIVM virological laboratory for respiratory pathogens. 
 
Definition of exposure and confounders 
The exposure of interest was prior IIV immunization among those immunized. For each child 
contributing to the analysis, we determined the immunization status per year and the immunization 
history for that same year, defined as i) no prior IIV immunization in previous three years, ii) one IIV in 
previous two years, iii) at least two IIVs in previous three years, including prior year. Children eligible for 
immunization, but without receipt of IIV in the current year did not contribute to that year’s analysis.  
Additional characteristics such as age, socio-economic status (SES), the total number of pre-existing 
medical conditions meeting eligibility criteria for IIV immunization per child, health-seeking behavior, 
and number of RI episodes outside the influenza season were considered as potential confounders. SES 
was derived from the postal code of each patient according to The Netherlands Institute for Social 
Research (SCP) containing information of income, percentage of people living in the area with low 
income, low education and unemployment.[29] SES levels were categorized according to postal code 
ranking in the Netherlands: high (top 20%), middle (20-80%) and low (lowest 20%). Health-seeking 
behavior was assessed by quantifying the number of primary care consultations for self-limiting 
diseases/complaints (ICPC codes). These included conditions such as exanthemaous diseases 
(chickenpox, exanthema subitum, hand foot mouth disease), acute gastrointestinal complaints (diarrhea, 
vomiting, abdominal pain) and focal symptoms (conjunctivitis, cold sore) To adjust for possible 
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confounding by indication, a co-variate representing the number of RI episodes in the months prior to the 
influenza season, between calendar weeks 20 to 36 (late spring and summer season), was added to the 
model. 
 
Statistical analysis  
For descriptive purposes, the incidence of RI episodes per 100 child-years was calculated by dividing the 
number of episodes by the total number of child-years per 5-year age categories. We used generalized 
estimating equations (GEE) with a binomial distribution and logit link function to assess the association 
between prior IIV immunization status and the presence of RI episodes during the influenza season with 
“current year vaccinated, but no prior IIV immunization” as the reference group. To test whether the 
effect of prior IIV immunization status on RI episodes was age-dependent, an interaction term for prior 
IIV immunization status with age was included in the fully adjusted GEE model. Effect modification was 
defined as p-value <0.10. The regression coefficients from the GEE model reflect odds ratios (OR). The 
fully adjusted model included age, SES, number of pre-existing medical conditions, health-seeking 
behavior and number of GP-diagnosed RI episodes outside the influenza season. 
 
Results 
Study population 
Over the years 2004-2015, 225,045 children were registered in the JHN or ZGA databases and 12,916 
children (5.7%) met the eligibility criteria for IIV immunization for at least one influenza season. Of 
these, 4,183 children (32% of 12,916) received IIV at least once during follow-up and were included in 
the analysis (total child-years of follow-up: 11,493). IIV immunization occurred in 10,017 follow-up 
years, whereas no IIV was administered in 1,476 child-years (Figure 1). 
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Baseline characteristics of the total study population and according to prior IIV immunization status are 
shown in Table 1. Immunized children with prior IIV immunization were older, had lower healthcare 
seeking and fewer RI episodes outside the influenza season than those without IIV history (p<0.001). The 
majority qualified for IIV due to pre-existing respiratory disease (78%) with asthma being the prime 
diagnosis. Overall, RI incidence rate was highest in the youngest age group and declined thereafter. The 
current year immunized group with prior IIV immunization had a lower RI incidence rate across all ages 
compared to those without IIV history.  
Impact of repeated IIV immunization on respiratory illness episodes  
Table 2 shows the association between prior IIV immunization and GP-diagnosed RI episodes during 
influenza seasons. Seasonal RI episodes occurred most frequently in IIV immunized children without 
history of IIV (7.0%). The adjusted model showed lower odds for having an RI episode during the 
influenza season in children with prior IIV immunization compared to those without prior IIV 
immunization (OR 0.61; 95%CI 0.47 to 0.78 for immunized in current year and one IIV in previous two 
years and OR 0.85, 95%CI 0.68 to 1.07 for immunized in current year and at least two IIVs in previous 
three years). The association between prior IIV immunization status and the occurrence of RI episodes 
during the influenza season was not age-dependent (Pinteraction =0.68). 
 
Discussion 
This study shows that protection against seasonal RI is not attenuated following repeated annual IIV 
immunization in children with pre-existing medical conditions. Interestingly, our findings suggest that 
repeated IIV immunization may even enhance protection. 
Concerns about possible attenuation of influenza immunity following repeated IIV were first raised by  
Hoskins et al. in the late 70s.[9] They found a decreased protection against influenza in boys who had 
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been immunized annually compared with first-time immunized boys attending boarding school. 
Subsequent epidemiological studies, however, have been inconsistent.[9-20, 30] which could be due to 
methodological shortcomings (e.g. small sample sizes, short follow-up periods or insufficient data to 
adjust for confounding) or may mean that the hypothesis is incorrect. Recently, Ramsay and colleagues 
published a systematic review and meta-analysis including all epidemiological studies in this field. [31] 
They concluded that there is no overall evidence that prior season vaccination does negatively impact 
vaccine effectiveness. However, they emphasized the lack of studies including multiple seasons to 
evaluate repeated vaccination in more detail. Our study is the first that used a large and comprehensive 
longitudinal primary care dataset spanning eleven influenza seasons; it is powered to reliably detect 
differential effects of IIV history, rule out distortions by annual fluctuations in IIV effectiveness and 
adjust for a range of confounders.  
 
Our study provides important evidence supporting that prior IIV immunization does not reduce, and in 
fact may even enhance vaccine effectiveness for seasonal RI by providing residual protection from earlier 
vaccinations.[15] Previous studies have primarily focused on laboratory confirmed influenza and we are 
the first to demonstrate this effect for seasonal RI. In addition, we found that the impact of repeated 
immunization was not modified by age. This is particularly reassuring in light of Bodewes et al’s 
suggestion that annual influenza immunization in immunologically naive children may prevent the 
induction of heterosubtypic immunity, thereby enhancing susceptibility to genetically more distant 
strains.[6, 8] Our observations do not support this, although we note that we had no information on prior 
exposure to natural influenza among immunized children. 
 
While laboratory confirmed influenza or markers of protective influenza immunity are considered the 
most specific endpoints to assess vaccine efficacy, the occurrence of RI during the annual influenza 
epidemic season, as studied here, is considered a reliable and comprehensive endpoint to assess IIV field 
effectiveness.[32] On average 25-30% of all GP-diagnosed RI episodes is attributed to influenza virus 
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infection during this period.[28] An advantage of studying these clinical, instead of microbiological or 
serological endpoints is that these are more relevant for daily practice. Our study was based on primary 
care attendance for RI, which reflects approximately 30-50% of respiratory symptom episodes occurring 
in the community.[33, 34] Although the effects of repeated IIV are likely similar for RI episodes that do 
or do not lead to GP consultation, our study was not designed to measure effects of repeated IIV stratified 
by disease severity. Future studies should therefore preferably also capture RI symptom episodes 
occurring in the community, as well as influenza and RI-associated hospitalizations. 
 
Some methodological limitations deserve further attention. First, due to the observational design of this 
study, we cannot entirely rule out residual confounding by indication, meaning that the most severely 
affected children are more likely to receive repeated IIV and at highest risk for experiencing RI. This 
could have led to an underestimation of the protective effect of repeated IIV. By including RI episodes 
outside the influenza season as proxy for disease severity in our model, it is unlikely that this significantly 
influenced our findings. Second, misclassification of the cumulative number of influenza immunizations 
is possible, but likely to be low. Vaccinations are supplied almost exclusively by GPs, and adherence to 
coding vaccine administration is high because of the financial incentive. Third, misclassification of the 
outcome may be differential if GPs were less inclined to diagnose influenza among vaccinated children 
due to its perceived effectiveness. However, since we used a range of ICPC codes indicating RI of which 
only one was exclusively used for influenza infection (R80, representing 4.7% of RI episodes) we 
consider this unlikely. Finally, the dataset does not contain information on ethnicity. However, less than 
13% of the population living in the Netherlands has a non-Western background.[35] Therefore, this study 
primarily looks at a white population in a high-income Northern European setting. This could have an 
effect on the generalizability of our results. However, we have no reason to assume that the impact of 
repeated IIV immunization differs by ethnic background or SES. 
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In summary, repeated IIV immunization has no negative impact on long-term vaccine effectiveness and 
may even enhance protection against RI among IIV immunized children with pre-existing medical 
conditions.  
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Table 1: Characteristics of the study population according immunization status 
Study population 
 
Total study population 
CY=11,493 
Immunized in current year, 
but no prior IIV 
immunization 
CY=2,914 
Immunized in current year, 
and  one IIV in previous two 
years 
CY=2,450 
Immunized in current year, 
and at least 2 IIVs in previous 
3 years, including prior year  
CY=4,653 
Sex (%)      
Boys 57.9 57.7 57.1 57.6 
Girls 42.1 42.3 42.9 42.4 
Socio-economic status score     
  Low 16.4 17.0 16.1 14.6 
  Middle 50.7 48.5 50.2 54.3 
  High 32.7 34.5 33.5 31.0 
Age groups (yr;%))     
  0-5 8.4 20.9 8.8 1.2 
  6-10 15.6 20.2 19.0 10.5 
  11-15 45.3 37.5 44.7 48.3 
  >15 30.7 21.7 27.6 39.9 
19 
 
Health-seeking behavior; 
number of consultations (%) 
    
  0 90.3 88.7 90.4 92.0 
  1 6.8 8.1 6.7 5.5 
  >1 2.9 3.2 2.8 2.6 
Out-season RI in previous 
year (%) 
    
  0 96.5 96.4 97.4 98.1 
  1 3.0 3.2 2.4 1.5 
  >1 0.5 0.3 0.2 0.3 
Indicated diseases; % yes      
  Pre-existing 
cardiovascular disease 
10.7 10.5 10.0 10.2 
  Chronic lung disease 78.0 79.7 77.3 78.5 
  Diabetes 8.3 6.3 8.5 9.2 
  Chronic kidney disorder 0.1 0.1 0.1 0.1 
  Immunocompromising  
condition 
3.9 3.7 4.6 3.3 
20 
 
  Respiratory difficulties    
  with neurological origin 
1.7 1.3 1.8 1.8 
Number of indications for 
IIV (%) 
    
  1 97.4 98.3 97.7 96.8 
  >1 2.6 1.7 2.3 3.2 
Incidence of RI during 
influenza season / 100 child-
years (95% CI) 
    
All ages 18.4 (17.1-19.8) 27.8 (24.7-31.2) 13.1 (10.8-15.7) 13.4 (11.7-15.4) 
  0-5 56.4 (48.6-65.1) 66.2 (55.6-78.2) 37.9 (25.5-54.4) 49.4 (24.1-90.8) 
  6-10 30.3 (26.0-35.0) 30.0 (23.0-38.4) 22.8 (16.1-31.3) 26.9 (19.7-35.9) 
  11-15 13.2 ( 11.5-15.0) 14.8 (11.3-19.1) 9.4 (6.6-12.9) 12.4 (9.7-14.8) 
  >15 9.6 (7.9-11.6) 12.6 (8.5-18.1) 4.5 (2.3-8.0) 10.4 (8.1-13.2) 
Boys 19.3 (17.6-21.3) 30.0 (25.7-34.7) 14.7 (11.5-18.5) 13.8 (11.5-16.5) 
Girls 17.1 (15.1-19.2) 24.8 (20.4-29.9) 10.9 (7.7-14.9) 12.9 (10.3-15.9) 
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Number of consultations for 
RI during influenza season 
(%) 
    
  0 95.2 93.0 96.5 96.3 
  1  3.0 3.9 2.3 2.5 
  >1 1.8 3.1 1.2 1.2 
Abbreviations: CY: Child-years, RI: respiratory infections, CI: confidence interval 
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Table 2: Association between immunization history and occurrence of at least one RI episode during influenza season 
 % RI episodes Crude OR (95% CI) Adjusted OR (95% CI) 
Immunized in current year, but no (recent) prior IIV 
immunization 
7.0 ref ref 
Immunized in current year, and  one IIV in previous two 
years 
3.5 0.48 (0.37-0.61) 0.61 (0.47-0.78) 
Immunized in current year, and at least 2 IIVs in 
previous 3 years, including prior year  
3.7 0.50 (0.41-0.62) 0.85 (0.68-1.07) 
*Adjusted for socio-economic status (SES), age, number of indication categories for IIV, health-seeking behavior, and number 
of out-season summer GP-diagnosed RI episodes. 
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Figure 1: Flowchart of the study population  
Number of children registered in JHN or ZGA 
primary care records between 
2004-2015
N=225,045
Children at least 1 year 
indicated for IIV 
N= 12,916
Child-years of children who 
are at least 1 year indicated 
for IIV 
Child-years= 42,954
Number of children 
eligible for study
N=4,183
Never vaccinated
N= 7,397
Unkown information on 
prior  vaccination status 
and/or prior year RI 
episodes
N=1,336
Number of child-years 
eligible for study
Child-years=11,493
Never vaccinated 
Child-years=26,161
Unkown information on prior 
year RI episodes and/or prior 
vaccination status 
Child-years=5,300
Ever IIV 
immunized, but not 
in current year
Child-years=1,476 
Immunized in 
current year
Child-years=10,017
…..AND
one IIV in previous two years
Child-years=2,450
…..BUT
no (recent) prior IIV 
immunization
Child-years=2,914
…..AND
at least 2 IIVs in previous 3 
years, including prior year
Child-years=4,653
 
Note: The results of the 1,476 child-years of follow-up of children eligible for IIV immunization, but without receipt of IIV in the current year are 
not reported in the results. 
